News | December 27, 2024
Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
Mankind Pharma has reported total income of Rs. 2768.07 crores during the period ended September 30, 2023
Prateek has more than 23 years of rich experience in Human Resource
Mankind Pharma commences the commercial operations newly set-up plant in Udaipur
Subscribe To Our Newsletter & Stay Updated
